ATE397019T1 - Herstellung von f(ab')2 fragmenten in saügetierzelle - Google Patents
Herstellung von f(ab')2 fragmenten in saügetierzelleInfo
- Publication number
- ATE397019T1 ATE397019T1 AT02789019T AT02789019T ATE397019T1 AT E397019 T1 ATE397019 T1 AT E397019T1 AT 02789019 T AT02789019 T AT 02789019T AT 02789019 T AT02789019 T AT 02789019T AT E397019 T1 ATE397019 T1 AT E397019T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- preparation
- mammal cells
- cells
- antibody fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0100917 | 2001-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397019T1 true ATE397019T1 (de) | 2008-06-15 |
Family
ID=19760784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789019T ATE397019T1 (de) | 2001-12-17 | 2002-12-17 | Herstellung von f(ab')2 fragmenten in saügetierzelle |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050048038A1 (de) |
| EP (1) | EP1456238B1 (de) |
| AT (1) | ATE397019T1 (de) |
| AU (1) | AU2002353662B2 (de) |
| CA (1) | CA2470579C (de) |
| DE (1) | DE60226896D1 (de) |
| DK (1) | DK1456238T3 (de) |
| ES (1) | ES2307807T3 (de) |
| NZ (1) | NZ533332A (de) |
| SI (1) | SI1456238T1 (de) |
| WO (1) | WO2003051927A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| AU2002351444B2 (en) | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| ATE397019T1 (de) | 2001-12-17 | 2008-06-15 | Crucell Holland Bv | Herstellung von f(ab')2 fragmenten in saügetierzelle |
| AU2004236440B2 (en) | 2003-05-09 | 2008-10-09 | Crucell Holland B.V. | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| MA49426B1 (fr) | 2017-10-02 | 2022-09-30 | Laboratorios Silanes S A De C V | Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2 |
| US20250270509A1 (en) * | 2022-04-18 | 2025-08-28 | John Paul Ii Medical Research Institute | Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0604580A1 (de) * | 1991-09-19 | 1994-07-06 | Genentech, Inc. | Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper. |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| CN100457914C (zh) * | 1999-04-15 | 2009-02-04 | 荷兰克鲁塞尔公司 | 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白 |
| EP1103610A1 (de) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Impfstoffherstellung von immortalisierten Säugetierzellinien |
| EP1130099A1 (de) * | 2000-02-25 | 2001-09-05 | Crucell Holland B.V. | Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper |
| ATE397019T1 (de) | 2001-12-17 | 2008-06-15 | Crucell Holland Bv | Herstellung von f(ab')2 fragmenten in saügetierzelle |
-
2002
- 2002-12-17 AT AT02789019T patent/ATE397019T1/de active
- 2002-12-17 ES ES02789019T patent/ES2307807T3/es not_active Expired - Lifetime
- 2002-12-17 SI SI200230701T patent/SI1456238T1/sl unknown
- 2002-12-17 CA CA2470579A patent/CA2470579C/en not_active Expired - Lifetime
- 2002-12-17 AU AU2002353662A patent/AU2002353662B2/en not_active Ceased
- 2002-12-17 NZ NZ533332A patent/NZ533332A/en not_active IP Right Cessation
- 2002-12-17 US US10/499,298 patent/US20050048038A1/en not_active Abandoned
- 2002-12-17 DE DE60226896T patent/DE60226896D1/de not_active Expired - Lifetime
- 2002-12-17 EP EP02789019A patent/EP1456238B1/de not_active Expired - Lifetime
- 2002-12-17 WO PCT/NL2002/000841 patent/WO2003051927A2/en not_active Ceased
- 2002-12-17 DK DK02789019T patent/DK1456238T3/da active
-
2008
- 2008-02-14 US US12/070,145 patent/US7537916B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003051927A2 (en) | 2003-06-26 |
| EP1456238A2 (de) | 2004-09-15 |
| EP1456238B1 (de) | 2008-05-28 |
| SI1456238T1 (sl) | 2008-08-31 |
| DE60226896D1 (de) | 2008-07-10 |
| ES2307807T3 (es) | 2008-12-01 |
| AU2002353662A1 (en) | 2003-06-30 |
| CA2470579C (en) | 2012-03-06 |
| DK1456238T3 (da) | 2008-08-18 |
| US20080166767A1 (en) | 2008-07-10 |
| US7537916B2 (en) | 2009-05-26 |
| WO2003051927A3 (en) | 2003-11-20 |
| NZ533332A (en) | 2005-07-29 |
| CA2470579A1 (en) | 2003-06-26 |
| US20050048038A1 (en) | 2005-03-03 |
| AU2002353662B2 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200001946T2 (tr) | Aşı | |
| DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
| TR200602095T2 (tr) | Hümanize Anti-LT-Beta-R antikorları | |
| ATE405647T1 (de) | Rekombinantes gelatin in impstoffen | |
| ATE397019T1 (de) | Herstellung von f(ab')2 fragmenten in saügetierzelle | |
| DK1443961T3 (da) | Glycoprotein-sammensætninger | |
| BR0015224A (pt) | Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado | |
| DK1157037T3 (da) | GCSF-konjugater | |
| ATE500323T1 (de) | Subtilisin-variante | |
| TR199801179T2 (xx) | Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri. | |
| AR032394A1 (es) | Una composicion oral. | |
| BR0109346A (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas | |
| FR15C0055I1 (de) | ||
| BR0215266A (pt) | Preparação liofilizada compreendendo anticorpos contra o receptor de egf | |
| EA200201214A1 (ru) | Замещенные тиоацетамиды | |
| IL172854A0 (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
| BR0314058A (pt) | Composições para cuidados pessoais a base de álcool ramificado | |
| PT1200561E (pt) | Clone celular recombinante estavel, sua producao e utilizacao | |
| NO20061470L (no) | Fremgangsmate for fremstilling av gamma-karboksylerte proteiner | |
| IS6654A (is) | Stöðugt gabapentín með pH innan stýrðra marka | |
| PL367306A1 (pl) | Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania | |
| TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
| ATE522223T1 (de) | Pflanzenextrakte | |
| TR200402070T4 (tr) | Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı | |
| BR0013221A (pt) | Chá preto de folha |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1456238 Country of ref document: EP |